Skip to main content
PepStack
Blutwerte · Marker

Fibrinogen

Plasma Fibrinogen · Gerinnungsfaktor I

Entzündungsmarker
Einheit:
g/L
Abbreviation
Fib

Fibrinogen test quantifies the concentration of fibrinogen, a glycoprotein involved in blood clot formation, in the plasma.

Reference Ranges

Reference
24g/L
2
2.5
3.5
4
LowNormalHigh
Reference
Optimal
Unit · g/L

Reference ranges may vary slightly based on laboratory standards.

Overview

Übersicht

Fibrinogen, also known as Plasma Fibrinogen or Gerinnungsfaktor I, is a glycoprotein that plays a critical role in blood coagulation. It is synthesized by the liver and circulates in the plasma. Upon vascular injury, fibrinogen is converted by thrombin into fibrin, which forms a mesh that stabilizes the blood clot. Researchers have found that fibrinogen levels can reflect the body's inflammatory status, as it is an acute-phase reactant that increases in response to inflammation. Clinically, elevated fibrinogen levels are associated with an increased risk of cardiovascular diseases, such as myocardial infarction and stroke, as well as conditions like deep vein thrombosis and disseminated intravascular coagulation (DIC). Conversely, low fibrinogen levels can indicate liver disease, disseminated intravascular coagulation, or congenital fibrinogen deficiencies, which may lead to bleeding disorders. In the context of athletic performance and biohacking, fibrinogen is of interest due to its role in inflammation and clot formation. Athletes may monitor fibrinogen levels to assess recovery and inflammation status. For longevity, maintaining optimal fibrinogen levels may be beneficial in reducing cardiovascular risk. However, researchers observed that fibrinogen levels can be influenced by various factors, including acute infections, stress, and hormonal changes. Time of day and fasting status do not significantly affect fibrinogen levels, but acute physical stress or recent surgery can temporarily alter results. Therefore, it is crucial to consider these factors when interpreting fibrinogen levels.

Klinische Bedeutung

Elevated fibrinogen levels indicate increased risk of cardiovascular diseases and thrombotic events. Reduced levels suggest potential bleeding disorders or liver dysfunction.

Dynamics

Trend Interpretation

Rising Values

Progressively rising fibrinogen levels suggest increasing inflammatory or thrombotic risk. Retest in 4-6 weeks if elevated.

Falling Values

Progressively falling fibrinogen levels may indicate resolution of inflammation or potential bleeding risk.

Re-test Interval

4 weeks if outside optimal range

Etiology

Causes — High & Low

Cause

Elevated Levels

  • Inflammation
  • Acute infection
  • Pregnancy
  • Smoking
  • Obesity
Cause

Low Levels

  • Liver disease
  • Disseminated intravascular coagulation
  • Congenital fibrinogen deficiency
  • Severe malnutrition
  • Acute blood loss
Protocol

How to Optimize

Lever

Lifestyle

  • Regular exercise
  • Smoking cessation
  • Weight management
Lever

Nutrition

  • Increase omega-3 fatty acids
  • Consume antioxidant-rich foods
Lever

Supplementation

  • Omega-3 supplements
  • Vitamin C

Note:

Consult a healthcare provider before starting any new supplementation, especially if you have underlying health conditions.

Testing Guidelines

Fasting Not Required
Not Time-Sensitive

Testing Frequency

Annually for adults at risk of cardiovascular disease.

Interfering Factors

  • Recent surgery
  • Acute infection
  • Hormonal therapy

Open Research Questions

Current research suggests that reference ranges for fibrinogen levels in specific populations, such as neonates and patients with dysfibrinogenemia, remain poorly defined. Researchers have not yet established optimal fibrinogen-to-albumin ratio targets for predicting outcomes in neonatal sepsis. Additionally, clinical questions remain unanswered regarding the long-term implications of fibrinogen alterations in various thrombotic and inflammatory conditions, particularly in the context of treatment efficacy and patient stratification.

29 Research Publications

616

Total Citations

12

Human/RCT

3.1

Avg. Influence

2025

Latest

Sort
Filter
#01

Laboratory diagnosis of dysfibrinogenemia.

ReviewInfluence6.0
120
This study reviewed dysfibrinogenemia, a coagulation disorder characterized by abnormal fibrinogen function. Researchers found that both inherited and acquired forms can lead to bleeding or thrombosis, and outlined laboratory tests for diagnosis.
View on PubMed
#02

Plasma Fibrinogen as a Biomarker for Mortality and Hospitalized Exacerbations in People with COPD.

HumanInfluence8.0
109
Researchers analyzed data to assess plasma fibrinogen as a biomarker for mortality and exacerbations in COPD patients. They found that high fibrinogen levels were associated with increased risks of hospitalizations and death, suggesting its potential role in clinical trials.
View on PubMed
#03

Laboratory and Genetic Investigation of Mutations Accounting for Congenital Fibrinogen Disorders.

ReviewInfluence4.0
98
This study reviewed congenital fibrinogen disorders, which can lead to bleeding issues. Researchers found that these disorders are caused by mutations in fibrinogen-encoding genes and can be classified into quantitative and qualitative deficiencies.
View on PubMed
#04

Defibrinogenating enzymes.

AnimalInfluence3.0
62
Researchers found that certain snake venoms can significantly reduce plasma fibrinogen levels through their proteolytic effects. The study highlights the potential use of these venoms in clinical settings for managing conditions like stroke and thrombosis, although further trials are needed to clarify their roles.
View on PubMed
#05

Fibrinogen and aging.

Human
53
This study found that plasma fibrinogen levels increase with age, which may correlate with higher risks of cardiovascular diseases. Researchers observed that fibrinogen levels rose significantly in older adults, indicating potential underlying health processes.
View on PubMed
#06

Laboratory testing for fibrinogen abnormalities.

ReviewInfluence1.0
48
Researchers summarized the laboratory testing methods for diagnosing fibrinogen disorders, which can lead to increased bleeding risk. The study discusses both acquired and congenital disorders and the importance of specialized tests.
View on PubMed
#07

Clotting factors: Clinical biochemistry and their roles as plasma enzymes.

ReviewInfluence2.0
35
Researchers described the coagulation process involving fibrinogen and its conversion to fibrin, which is crucial for blood clot formation. They emphasized the importance of laboratory testing for diagnosing bleeding and thrombotic disorders.
View on PubMed
#08

Pretreatment plasma fibrinogen level as a prognostic biomarker for patients with lung cancer.

Meta-AnalysisInfluence1.0
28
This meta-analysis assessed the prognostic value of pretreatment plasma fibrinogen levels in lung cancer patients. Researchers found that higher fibrinogen levels were significantly associated with worse overall survival and advanced disease stage.
View on PubMed
#09

Reference limits of plasma fibrinogen.

HumanInfluence2.0
25
This study established reference limits for plasma fibrinogen in healthy individuals and examined its relationship with various factors. Researchers found that fibrinogen levels increased with age and were influenced by body weight and smoking.
View on PubMed
#10

Disseminated intravascular coagulation.

Review
11
This study examined disseminated intravascular coagulation (DIC) in obstetrics, highlighting its association with severe maternal and perinatal outcomes. Researchers found that a combination of laboratory tests, including plasma fibrinogen levels, is necessary for diagnosis, as no single test is sufficient.
View on PubMed

Clinical Trials (5)

5

Total Trials

1,713

Total Enrolled

Point of Care Fibrinogen Measurement in Trauma Patients in the Emergency Department

NCT07097337RECRUITING
Sponsor

Erasmus Medical Center

Enrollment

150

Started

2025

Primary outcome

Feasibility of qLabs Fib testing in the emergency department

Trauma Induced CoagulopathyTrauma CoagulopathyFibrinogen DeficiencyFibrinogen; Deficiency, AcquiredMassive Transfusion ProtocolMassive Hemorrhage

The Predictive and Prognostic Values of the Fibrinogen to Albumin Ratio and C-reactive Protien to Albumin Ratio in Systemic Lupus Erythematosus Patients

Sponsor

Sohag University

Enrollment

150

Started

2024

Primary outcome

Fibrinogen/Albumin ratio, C-reactive protein /Albumin ratio

Systemic Lupus Erythematosus

Association of Genetic Polymorphisms With Atrial Fibrosis and Thrombogenic Substrate in Patients With Non-valvular Atrial Fibrillation

Sponsor

Memorial Ankara Hospital

Enrollment

225

Started

2018

Primary outcome

Associations between polymorphic genetic variants and atrial fibrosis

Atrial FibrillationThrombosisStrokeGenetic PredispositionHeart Diseases

Determination of Fibrin Activity in Plasma on STA-R® Prototype

NCT02856789COMPLETED
Sponsor

Diagnostica Stago R&D

Enrollment

913

Started

2016

Primary outcome

Dynamic evolution of the number of protofibrils

Blood Coagulation DisordersThrombotic DisordersHemorrhagic DisordersTrauma

Phase IIb Study to Evaluate the Efficacy and Safety of GFT505 Versus Placebo in Patients With Non-Alcoholic Steatohepatitis (NASH)

NCT01694849Phase 2COMPLETED
Sponsor

Genfit

Enrollment

275

Started

2012

Primary outcome

Percentage of Responders With Disappearance of Steatohepatitis Without Worsening of Fibrosis (ie, Participants no Longer Meeting the Criteria for Steatohepatitis)

Non-Alcoholic Steatohepatitis (NASH)

Publication Trend

Research publications about Fibrinogen over time

9total
1
'94
1
'97
1
'01
1
'02
1
'08
1
'13
1
'14
1
'20
1
'23

Track your bloodwork in PepStack

Log lab results, track trends and optimize your biomarkers over time.

Legal Disclaimer

This page is for informational and research purposes only. All information is based on published scientific literature and does not constitute medical advice, diagnosis, or treatment recommendations. Many substances listed may not be approved for human use and may be subject to drug regulation laws (e.g., AMG in Germany, FDA in the US). PepStack does not encourage the use of any substance on humans. Always consult a qualified healthcare professional before making any health-related decisions. Use of this information is entirely at your own risk. PepStack assumes no liability for the accuracy, completeness, or timeliness of the content provided. Full disclaimer